N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Trial details
- Registry ID
- NCT06061809
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809 | IBRX | Phase 2 | Active not recruiting | 2029-12-31Estimated |
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399 | IBRX | Phase 2 | Active not recruiting | 2025-10-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |